Financial Consulate’s Sinovac Biotech, Ltd SVA Stock Holding History

Financial Consulate’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	23	–	–	﹤0.01%	1503
2025 Q4	$0	Hold	23	–	–	﹤0.01%	1461
2025 Q3	$0	Buy	+23	New	–	﹤0.01%	1154

Other funds holding SVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Financial Consulate's SVA Position: Q1 2026 in Review

Financial Consulate held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 23 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Financial Consulate first reported a position in SVA in Q3 2025 and has held it in 3 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

Financial Consulate held 23 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
Financial Consulate left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1503 holding.
Financial Consulate first reported a position in Sinovac Biotech, Ltd in Q3 2025 and has held it in 3 quarters since.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.